BNP Fast Test Kit

BNP Fast Test Kit

BNP Fast Test Kit by Getein is a rapid and reliable solution for detecting B-type natriuretic peptide in plasma or whole blood. Ideal for diagnosing heart failure and assessing cardiac risk, with results in 10 minutes.

Description

BNP Fast Test Kit (Immunofluorescence Assay)

The BNP Fast Test Kit is an advanced immunofluorescence assay designed for the quantitative detection of B-type natriuretic peptide (BNP) in human plasma and whole blood. It delivers quick, reliable results within just 10 minutes, making it ideal for point-of-care testing in emergency and cardiology settings. This test supports the diagnosis and risk assessment of congestive heart failure (CHF) and acute coronary syndromes (ACS).

Key Advantages

  • Rapid Testing: Delivers results in only 10 minutes
  • Wide Detection Range: 5.0–5000.0 pg/mL for accurate quantification
  • Sample Versatility: Compatible with plasma and whole blood samples
  • Long Shelf Life: Stable for up to 24 months from manufacturing date

About BNP

B-type natriuretic peptide (BNP) is a hormone secreted primarily by the heart in response to increased pressure within the ventricles. It plays a crucial role in cardiovascular homeostasis by regulating blood pressure and fluid balance. Elevated BNP levels are strongly associated with heart failure and are valuable for diagnosis, prognosis, and treatment monitoring in patients with cardiac conditions.

Specifications

Parameter Details
Test Item BNP
Sample Type Plasma, Whole Blood
Detection Method Immunofluorescence Assay
Detection Range 5.0–5000.0 pg/mL
Cut-off Value 100.0 pg/mL
Test Time 10 Minutes
Storage Conditions 4–30°C
Shelf Life 24 Months

Compatible Devices

  • Getein 1100 Immunofluorescence Quantitative Analyzer
  • Getein 1160 Immunofluorescence Quantitative Analyzer
  • Getein 1180 Immunofluorescence Quantitative Analyzer
  • Getein 1200 Immunofluorescence Quantitative Analyzer
  • Getein 1600 Immunofluorescence Quantitative Analyzer

Clinical Applications

  • Diagnosis and severity assessment of congestive heart failure (CHF)
  • Risk stratification in patients with acute coronary syndromes (ACS)
  • Differential diagnosis of dyspnea and cardiac insufficiency
  • Monitoring and prognostic evaluation of heart failure treatment
  • Support in ruling in or ruling out heart failure (HF)